抗DIO3抗体 | Anti-DIO3 Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

Western Blot: DIO3 Antibody [NB110-96414] - Detection of Dio3 in rat placenta

Immunohistochemistry-Paraffin: DIO3 Antibody [NB110-96414] - IHC analysis of a formalin fixed paraffin-embedded (FFPE) human placenta using 1:50 dilution of DIO3 antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) was performed using Aperio AT2 (Leica Biosystems). Cytoplasmic staining in decidual cells was observed. Staining was performed by Histowiz.

目次に戻る

Background

DIO3 (type III iodothyronine deiodinase), an iodothyronine deiodinase family member, is expressed in placenta and several fetal tissues in the plasma/endosomal membranes as single-pass type II membrane protein, and it catalyzes the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into RT3 (3,3',5'-triiodothyronine) and of T3 (3,5,3'-triiodothyronine) into T2 (3,3'-diiodothyronine), both RT3 and T2 being inactive metabolites thus preventing premature exposure of developing fetus to adult levels of thyroid hormones. DIO3 controls circulating thyroid hormone levels throughout gestation by controlling thyroid hormone inactivation during embryological development. DIO3 is homodimeric and may undergo minor heretodimerization with DIO1 or DIO2, homo- or heterodimer state being critical for its catalytic activity. Its activity has been identified in only a limited number of postnatal tissues, i.e. brain, skin, and pregnant uterus, whereas it is abundantly present in several fetal tissues. Furthermore, DIO3 re-expression has been shown in certain pathologies that include cancer, cardiac hypertrophy, myocardial infarction, chronic inflammation, and critical illness.

目次に戻る